David Hurwitz has over 15 years of experience in healthcare business, market research, and policy; he is currently a medical student at University of Maryland. David began his career building a market research consulting business at ZS Associates, focusing on new drug launches. He had several roles at Genzyme Corporation, including Director of Marketing for a surgical device business, and product development roles for Genzyme’s surgical device and renal drug units. Most recently, Mr. Hurwitz was a Division Director at the Center for Medicare and Medicaid Innovation at CMS, where he developed and tested new payment and service delivery models. He holds an MBA from Harvard Business School and a BA from Yale University.
Robb Lawrence is a health care entrepreneur and strategist. Robb is the founder and current CEO of Chesapeake Therapeutics, a pharmaceutical company focused on unique reformulations of established products. Prior to Chesapeake, Robb founded Salient Consulting LLC (“Salient”), a boutique consultancy designed to help pharmaceutical companies inform key strategic decisions that defined product, pipeline and portfolio strategies. From 2009 - 2014 Robb oversaw the daily operations and growth and in 2014, Salient merged its operations with Applied Strategic LLP, an established strategy consulting practice based in London.
Prior to founding Salient, Mr. Lawrence held multiple marketing and commercial operations roles at Merck and Company. He was responsible for the development of core strategic elements of the go-to-market strategy for JANUVIA and Merck’s diabetes franchise. He subsequently oversaw multiple elements of the launch execution and developed the initial lifecycle strategy for the franchise.
Mr. Lawrence has a MBA in Marketing and Health Sector Management from Duke University and BA in Literature and History from Wake Forest University.